Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Cardiol Therapeutics ( (TSE:CRDL) ) just unveiled an announcement.
Cardiol Therapeutics Inc., a late-stage life sciences company specializing in anti-inflammatory and anti-fibrotic treatments for heart disease, is advancing its lead drug candidate CardiolRx for pericarditis, myocarditis, and heart failure, supported by the FDA’s Orphan Drug Designation in pericarditis. The company’s clinical pipeline includes the completed Phase II MAvERIC-Pilot and ARCHER studies, the ongoing pivotal Phase III MAVERIC trial in recurrent pericarditis, and development of its novel subcutaneous formulation CRD-38 for inflammatory heart disease, including heart failure.
On May 14, 2026, Cardiol announced it will participate in a fireside chat at the H.C. Wainwright 4th Annual BioConnect Investor Conference at the NASDAQ in New York on May 19, 2026. The appearance, which will be webcast live and archived for 90 days, is expected to spotlight the company’s late-stage cardiovascular programs and provide investors with further insight into its clinical and development strategy.
The most recent analyst rating on (TSE:CRDL) stock is a Buy with a C$9.00 price target. To see the full list of analyst forecasts on Cardiol Therapeutics stock, see the TSE:CRDL Stock Forecast page.
Spark’s Take on CRDL Stock
According to Spark, TipRanks’ AI Analyst, CRDL is a Neutral.
The score is held back primarily by weak financial performance (pre-revenue, sizable losses, and sustained cash burn), partially offset by a low-debt balance sheet. Technicals are a positive contributor with an improving uptrend and constructive momentum, while valuation remains constrained due to negative earnings and no dividend support.
To see Spark’s full report on CRDL stock, click here.
More about Cardiol Therapeutics
Cardiol Therapeutics Inc. is a late-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for heart disease. Its lead small-molecule candidate, CardiolRx, targets inflammasome pathway activation in conditions such as pericarditis, myocarditis, and heart failure, and the company is also advancing CRD-38 for inflammatory heart disease, including heart failure.
Average Trading Volume: 134,543
Technical Sentiment Signal: Buy
Current Market Cap: C$207M
Learn more about CRDL stock on TipRanks’ Stock Analysis page.